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Abstract
The 22Rv1 cell line is widely used for prostate cancer research and other studies throughout the world. These cells were
established from a human prostate tumor, CWR22, that was serially passaged in nude mice and selected for androgen
independence. The 22Rv1 cells are known to produce high titers of xenotropic murine leukemia virus-related virus (XMRV).
Recent studies suggested that XMRV was inadvertently created in the 1990’s when two murine leukemia virus (MLV)
genomes (pre-XMRV1 and pre-XMRV-2) recombined during passaging of the CWR22 tumor in mice. The conclusion that
XMRV originated from mice and not the patient was based partly on the failure to detect XMRV in early CWR22 xenografts.
While that deduction is certainly justified, we examined the possibility that a closely related virus could have been present in
primary tumor tissue. Here we report that we have located the original prostate tumor tissue excised from patient CWR22
and have assayed the corresponding DNA by PCR and the tissue sections by fluorescence in situ hybridization for the
presence of XMRV or a similar virus. The primary tumor tissues lacked mouse DNA as determined by PCR for intracisternal A
type particle DNA, thus avoiding one of the limitations of studying xenografts. We show that neither XMRV nor a closely
related virus was present in primary prostate tissue of patient CWR22. Our findings confirm and reinforce the conclusion
that XMRV is a recombinant laboratory-generated mouse virus that is highly adapted for human prostate cancer cells.
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Introduction
The xenotropic murine leukemia virus-related virus (XMRV) is
a gammaretrovirus discovered during studies of prostate cancer
patients with a subtle genetic deficiency in the gene for the
antiviral protein RNase L [1]. While several subsequent studies
provided additional evidence for either XMRV or a closely related
virus in prostate cancer patients [2–6], more studies either failed to
detect any evidence of XMRV in prostate cancer patients or
evidence was obtained but was limited to a small number of
human samples [7–16]. Some of the positive findings in prostate
cancer including, but not limited to, integration site mapping and
detection of PCR products were later found to be the result of
laboratory contamination [17,18]. Possible sources of contamina-
tion include mouse DNA harboring MLV proviruses, XMRV
plasmid or PCR products, and XMRV itself from infected cell
lines. For instance, mouse DNA is sometimes present at trace
amounts in some Taq polymerases, PCR master mix preparations
and DNA extraction kits leading to false positives in PCR assays
[19–22]. False negatives can also be produced in PCR assays
further confounding detection of XMRV or related viruses [23]. A
single study also showed the presence of XMRV in chronic fatigue
syndrome patients [24], but recently those results have been
largely attributed to laboratory contamination [25–27] and the
original report was retracte [28]. Based on a recent large-scale
study of blood donors in the US, it is unlikely that XMRV per se
has entered this human population to any significant extent (0%
prevalence; 95% confidence interval 0%–0.017%) [29]. Never-
theless, some of the positive findings involving non-PCR based
methods, such as serology, immunohistochemistry and fluores-
cence in situ hybridization (FISH), that have seemingly detected
XMRV or similar viruses in human samples have yet to be fully
explaine [1,3,24]. Such evidence leaves open the possibility that
either mouse DNA or an XMRV-like virus is present in at least
some humans.
Against this backdrop, the origin of XMRV was recently
elucidated by studying the human prostate cancer cell line, 22Rv1,
and its xenograft precursors grown in nude mic [30]. The 22Rv1
cells are infected with, and produce high titers of, an XMRV that
is nearly identical in sequence to XMRV strain VP62 from
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traced back to a human prostate carcinoma (Gleason grade of 9)
that was excised in 1992 at Case Western Reserve Universit [32].
Subsequently, the tumor, dubbed CWR22, was serially trans-
planted in nude mice. In 1996, after four years of serial passage in
nude mice, castration of the mice was performed leading to
regression and relapse of the tumo [33]. The resultant androgen-
independent tumor, CWR22R, was then serially transplanted in
mice until 1999 when it was used to establish the 22Rv1 cell lin
[34]. High levels of XMRV are present in the 22Rv1 cell lines and
in late passages of the CWR22 tumor, but not in early xenograft
[30,35]. Remarkably, the host mice contain two proviruses, pre-
XMRV1 and pre-XMRV2, with long stretches (.3.2 kb) that are
99.9% identical to XMR [30]. It was hypothesized that
recombination between the two proviruses led to XMRV and
that XMRV was absent from the original tumor. However, the
original tumor samples were not evaluated in those reports while
xenografts inevitably contain low levels of mouse cells. The
presence of endogenous mouse proviruses in the DNA of such
contaminating mouse cells limits the choice of probes and PCR
primers that could be used to uniquely identify XMRV-like
elements in those samples. Here we describe the analysis of
paraffin-embedded prostate blocks from patient CWR22 and show
that neither XMRV nor closely related viruses are present in the
primary tumor.
Materials and Methods
Processing of Prostate Tissue Blocks
Processing of formalin-fixed and paraffin-embedded (FFPE)
blocks was performed in the Genomic Medicine Institute and
Department of Laboratory Medicine, Cleveland Clinic. Five
prostate tissue paraffin blocks from patient CWR22 (labeled A,
B, C, E, and K) were sectioned at a width of 5 m on a microtome
that had been used exclusively for human samples. Sections were
either collected in tubes for DNA extraction or placed on
microscope slides for FISH analysis. Sections were stored in a
4uC refrigerator in the Genomic Medicine Institute biorepository
(Cleveland Clinic). DNA extraction was performed in the same
laboratory in which neither XMRV nor XMRV plasmid was ever
used. The tissue collected originally from which the CWR22
transplant was produced was discarded tissue and no patient
consent was required.
Extraction of DNA from prostate sections
DNA extraction was performed by the following method
(provided by Dr. Charis Eng, Genomic Medicine Institute,
Cleveland Clinic: http://www.lerner.ccf.org/gmi/gmb/methods.
php). Deparaffinization was done by adding 1 ml xylene to
18 sections (5 m width each), shaking gently for 10 min, centrifu-
gation for 10 min at 16,000 g at room temperature and discarding
the supernatants. This step was repeated twice. The extraction was
then performed with 1 ml each of 100% ethanol (2 times), 80%
ethanol (2 times) and 50% ethanol (2 times), each time centrifug-
ing for 10 min at 16,000 g at room temperature and discarding
the supernatants. To the pellet 1 ml of nuclease-free water (USB/
Affymetrix) was added and incubated at 4uC overnight. The pellet
was collected after centrifugation for 10 min at 16,000 g at room
temperature after discarding the supernatant. Nucleic Acid Lysis
buffer, 700 ml, (10 mM Tris Base, 400 mM NaCl, 2 mM
Na2EDTA and 0.7% SDS), was added to the pellet. Proteinase
K, 50 ml (30 mg/ml) (Invitrogen) was added and digestion was
performed at 65uC for 24 hrs. An additional 50 ml of proteinase K
solution was added, incubated overnight at 65uC, 250 mlo f6M
NaCl was added, mixed thoroughly, and left at room temperature
for 10 min. Samples were centrifuged for 10 min at 16,000 g at
room temperature to pellet the DNA and supernatants were gently
discarded. Pellets were washed with 70% ethanol and air dried on
the bench top for a few min. Each pellet was resuspended in 40 ml
TE (10 mM Tris-HCl pH 8.0; 1 mM EDTA) (USB/Affymetrix)
and stored at 4uC.
Single nucleotide polymorphism (SNP) genotyping
(Roswell Park Cancer Institute)
SNP genotyping was performed using the MassARRAY
Compact system (Sequenom, Inc., San Diego, CA) on a panel of
30 custom SNP assays designed using RealSNP and MassARRAY
Assay Designer (Sequenom). Briefly, the protocol involves PCR
amplification of 10 ng DNA using SNP specific primers, followed
by a base extension reaction using the iPLEX Gold chemistry
(Sequenom). The final base extension products were treated and
spotted on a 384-pad SpectroCHIP (Sequenom) using a
ChipSpotter LT nanodispenser (Samsung). A MassARRAY
Analyzer Compact MALDI-TOF MS (Sequenom) was used for
Table 1. SNP Genotyping of CWR22 primary tumor, CWR22
xenograft, and 22Rv1 cells.
SNP ID Detected allele
rs10083901 A
rs1080169 C
rs10853605 C
rs1397266 AG
rs1559806 CT
rs16952692 C
rs16952847 A
rs16953030 A
rs17736674 A
rs17743658 A
rs1789223 C
rs2027735 T
rs2282543 T
rs2298617 G
rs2442962 G
rs2584076 T
rs35952031 G
rs3764466 G
rs4128208 C
rs4390682 A
rs4456603 A
rs4711374 C
rs608986 G
rs61751988 G
rs620898 T
rs7229495 G
rs7235543 T
rs7238500 A
rs75667697 T
rs77386888 A
doi:10.1371/journal.pone.0036072.t001
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were called using MassARRAY Typer Analyzer v4.0 (Sequenom).
Quantitative PCR (qPCR) for XMRV (Cleveland Clinic)
DNA samples were diluted to 100 ng/ml in TE buffer and 2 ml
(200 ng) aliquots were used in duplicate for the qPCR assays
(except for sample K, 17 ng of DNA was used due to a lesser
amount of available DNA). Fast Mastermix (Applied Biosystems)
was used for the qPCR assays using a Step One Plus Real time
PCR machine following the manufacturer’s instructions (Applied
Biosystems). PCR conditions for using PCR Fast Mastermix were:
95uC for 20 sec for initial denaturation followed by 95uC for 1 sec,
60uC for 20 sec (data collection step), repeated for 50 times. The
oligonucleotide probes contained 6-carboxyfluorescein (FAM)
linked to the 59 end and Nonfluorescent Quencher-Minor Grove
Binder (NFQ-MBG) linked to the 39 end (Applied Biosystems].
env gene:
6124F: 59-GGCCGAGAGAGGGCTACT-39
6159R: 59-FAM-CACATCCCCATTTGCC-NFQ-MGB-39
6197R: 59-TGATGATGATGGCTTCCAGTATGC-39
gag gene:
625F: 59-GTAACTACCCCTCTGAGTCTAACCT-39
668F: 59-FAM-TCCAGCGCATTGCATC-NFQ-MGB-39
708R: 59-CTTCTTGACATCCACAGACTGGTT-39
pol gene:
4843F: 59-CGGGACAGAACTATCCAGTATGTGA-39
4873F: 59-FAM-ACCTGCACCGCCTGTG- NFQ-MGB-39
4912R: 59-TGGCTTTGCTGGCATTTACTTG -39
As an internal control, we measured levels of the RNase P gene
(a single-copy gene) encoding the RNA moiety for the RNase P
enzyme. VIC-labeled control RNase P primer-probe combination
from Applied Biosystems was used. A known copy number of the
full length XMRV VP62 genome in plasmid pcDNA 3.1 [36] was
used as a positive control to test each primer-probe combination.
Intracisternal A-particles (IAP) qPCR assays (Cleveland
Clinic)
QPCR for mouse IAP DNA was performed with the following
oligonucleotide primers/probe:
IAP-1414F: 59-TGGCGAAAGTCAGCGTACTG-39
IAP-1435F: 59-FAM-TCAACCTCCCGGCAGT-NFQ-MGB-
39
IAP-1472R: 59-CATAGGGCGGACCTTGAAAC-39
As a positive control for IAP, mouse tail DNA was extracted
using Qiagen DNA extraction kit, its concentration measured by
absorbance and serially diluted in TE buffer to generate the
standard curve. PCR conditions were the same as those used to
detect XMRV sequences.
Figure 1. The sensitivity and specificity of qPCR assays were demonstrated with linear regression curves for XMRV VP62 plasmid
and mouse tail DNA. (A) Nine different dilutions of XMRV VP62 plasmid (15 to 15610
9 copies each reaction in duplicate) were used to generate the
standard curve using gag, pol and env primer probe combinations. (B–D) Serial dilution of mouse tail DNA (1 fg to 100 ng each reaction in duplicate)
were used to generate the data for (B) gag, (C) env and (D) IAP. e, exponent (10 to the power of n).
doi:10.1371/journal.pone.0036072.g001
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Single-round real-time reverse transcriptase polymerase chain
reaction (RT-PCR) prototype assays were run on the m2000rt
TM
(Abbott Molecular Inc., Des Plaines, IL) instrument. An average of
500 ng of DNA from prostate cancer patient CWR22 (blocks A, B,
C, E and K) was amplified with two primer sets designed to
individually target the polymerase (pol) or envelope (env) regions of
the XMRV genome. Each DNA sample diluted in water to
achieve a 25 ml volume was combined with 25 ml of master mix
that contained 10x EZ buffer, rTth enzyme, dNTPs, Rox
reference dye, MnCl2, primers, and probes, to obtain a final
PCR reaction volume of 50 ml. Primer/probe sequences, cycling
conditions and the sensitivity/specificity estimation of pol and env
RT-PCR assays have been described in detail previousl [37]. A
primer/probe set for detecting the 136 bases of human b-globin
gene was used to control for specimen adequacy and was amplified
and detected simultaneously with XMRV (Fam signal) in the same
reaction with a different fluorescence dye (Cy5 signal). TE buffer
containing 1.5 mg/mL of poly dA:dT was used as assay negative
control (NC). XMRV VP62 DNA plasmid diluted in the NC was
used as assay positive control (PC).
Fluorescence in situ hybridization (FISH) (Abbott
Diagnostics)
The XMRV-SO FISH probe was prepared by directly labeling
the entire plasmid DNA (,13.6 kb) of clone VP62/pcDNA3.1
carrying a full-length genome (,8.2 kb) of XMRV VP62 (36) with
Figure 2. An absence of detectable levels of XMRV DNA or closely related DNA in CWR22 primary prostate tissues was determined
by qPCR analysis. Amplification plot of real-time qPCR analysis for the (A) detection of XMRV specific regions (gag, pol and env) using XMRV VP62
plasmid DNA (3,750 copies) and (B) in DNA extracted from different sections of CWR22 prostate tissues (tissue blocks A, B, C & E, each assayed in
duplicate). For block C only, 1 of 2 assay for env was weakly positive, all other assays for gag, pol and env were negative. RNase P probes were used to
detect the presence of genomic DNA in tumor tissues.
doi:10.1371/journal.pone.0036072.g002
Table 2. Summary of XMRV and Control Assays in CWR22
Prostate Samples.
Prostate Block of
Patient CWR22 A B C E K
PCR-Cleveland Clinic
(XMRV gag)
2, 22 , 22 , 22 , 22 , 2*
PCR-Cleveland Clinic
(XMRV pol)
2, 22 , 22 , 22 , 22 , 2*
PCR-Cleveland Clinic
(XMRV env)
2, 22 , 22 , +/2** 2, 22 , 2*
PCR-Cleveland Clinic
(RNase P)
++ + + +
PCR-Cleveland Clinic (IAP) 2 +/2*** 22 2
PCR-Abbott (XMRV pol) 22 2 2 2
PCR-Abbott (XMRV env) 22 2 2 2
PCR-Abbott (b-globin) ++ + + +
FISH-Abbott (XMRV) 22 2 2 2
FISH-Abbott (CEP8) ++ + + +
*Reduced input DNA amount to 17 ng, **Ct value of 45, *** Ct value of 41.
doi:10.1371/journal.pone.0036072.t002
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described previousl [38,39]. The percent incorporation of
SpectrumOrange in the XMRV-SO probe was ,8%. CEP8-SA
probe derived from the centromeric sequence of human chromo-
some 8 and directly labeled with SpectrumAqua fluorophore was
obtained from Abbott Molecular, Inc.
For evaluation of XMRV FISH probe performance, XMRV
uninfected DU145 prostate cancer cell [36] were used as a
negative control, while 22Rv1 prostate cancer cells harbouring
,10 integrated copies of XMRV per cell and generating high–
titer XMRV virus [31] were used as a positive control. Both cell
lines were grown in DMEM-F12 complete medium (Invitrogen,
Carlsbad, CA) at 37uC in the presence of 5% CO2. After reaching
60%–70% confluence, 1 ml of colcemid solution (10 mg/ml;
Invitrogen) was added per 50 ml culture medium and cells were
cultured at 37uC for 2 hr. Cells were harvested after trypsiniza-
tion, washed once with 40 ml of 1x DPBS (Invitrogen),
resuspended in 40 ml of 0.075 M potassium chloride solution
(Invitrogen), and incubated at 37uC for 30 min. Cells were
subsequently washed with 40 ml of Carnoy’s fixative (3:1 v/v
methanol:glacial acetic acid; Fisher, Pittsburgh, PA) four times,
resuspended in 5 ml of Carnoy’s fixative and stored at 220uC.
Slides with a mixture of DU145 and 22Rv1 were prepared by
depositing 10 ml of each cell suspension on a SuperFrost Plus
positively charged slide (ThermoShandon, Pittsburgh, PA). The
slide was air-dried overnight prior to FISH pretreatment and
hybridization.
Cell specimen slides were pretreated in 2x SSC (0.3 M NaCl,
0.03 M sodium citrate, pH 7.0; Invitrogen) at 73uC for 2 min then
incubated in 0.5 mg/ml pepsin in 10 mM HCl (USB, Cleveland,
OH) at 37uC for 10 min. Slides were rinsed in 1x DPBS
(Invitrogen) for 5 min at room temperature, fixed in 1% neutral-
buffered formalin solution (Fisher) for 5 min, then immersed in 1x
DPBS for 5 min. Slides were dehydrated in an ethanol series of
70%, 85%, and 100% for 1 min each, and then air-dried. Ten ml
of hybridization solution was prepared by mixing 100 ng XMRV-
SO, 100 ng CEP8-SA, 1000 ng sonicated human placental DNA,
250 ng human Cot-1 DNA, and 7 ml LSI/WCP hybridization
buffer (Abbott Molecular, Inc.), and was applied to each slide. A
coverslip (22622 mm; VWR, Radnor, PA) was placed over the
probe solution, and sealed to the slide with rubber cement (Staples,
Framingham, MA). Probes and cell nucleic acids on each slide
were co-denatured at 73uC for 3 min and then hybridized at 37uC
for 16–24 hrs on a hybridization platform (ThermoBrite; Abbott
Molecular, Inc.). After hybridization, slides were washed in 0.4x
SSC/0.3% NP-40 (Abbott Molecular, Inc.) for 2 min at 73uC and
then in 2x SSC/0.1% NP-40 (Abbott Molecular, Inc.) for 1 min at
room temperature. Ten ml of nuclear counterstain DAPI II
(125 ng/ml; Abbott Molecular, Inc.) was applied to each
specimen, and slides were evaluated under a fluorescence
microscope. XMRV-SO probe was visualized with an orange
filter set, CEP8-SA probe was visualized with an aqua filter set,
and DAPI nuclear staining was visualized with a DAPI filter set.
Slides mounted with FFPE prostate cancer tissue sections were
baked at 56uC for 4 hrs then stored at room temperature. In
preparation for FISH hybridization, tissue specimen slides were
deparaffinized three times in Hemo-De solvent (Scientific Safety
Solvents, Keller, TX) for 5 min each at room temperature and
rinsed in absolute ethanol twice for 1 min each. Slides were
subsequently pretreated in a solution of 45% formic acid (Fisher)/
0.3% hydrogen peroxide (Calbiochem, San Diego, CA) for 15 min
at room temperature and rinsed in H2O for 3 min. Slides were
then incubated in pretreatment solution (Abbott Molecular, Inc.)
at 80uC for 35 min, washed in H2O at room temperature for
3 min, incubated in a pepsin solution (1.5 mg/ml in 0.1 N HCl) at
37uC for 22 min, rinsed in H2O at room temperature for 3 min.
Slides were subsequently dehydrated in 70%, 85%, and 100%
ethanol for 1 min each, and allowed to dry at room temperature.
Ten ml of probe hybridization mix containing 100 ng XMRV-SO,
100 ng CEP8-SA, 1000 ng sonicated human placental DNA,
250 ng human Cot-1 DNA, and 7 ml LSI/WCP hybridization
buffer was placed over each tissue section. A coverslip was applied
and edges were sealed to the slide with rubber cement. Probes and
tissue specimen nucleic acids on each slide were co-denatured for
5 min at 73uC and hybridized for 16–24 hr at 37uCo na
ThermoBrite. After hybridization, slides were placed in 2x SSC/
0.1% NP-40 at room temperature for 5–10 min, washed in 0.4 x
SSC/0.3% NP-40 at 73uC for 2 min and in 2 x SSC/0.1% NP-40
at room temperature for 1 min. Ten ml of nuclear counterstain
DAPI I (1,000 ng/ml; Abbott Molecular, Inc.) was applied to each
tissue section, and slides were evaluated under a fluorescence
microscope.
Ethical Statement
These studies were approved by the Cleveland Clinic Founda-
tion Institutional Review Board #1.
Results
Identification and verification of CWR22 prostate tissues
In 1992, prostate cancer patient CWR22 underwent transure-
thral resection of the prostate at Case Western Reserve Universit
[32]. Following surgery, chips of prostate tissue were fixed in 10%
neutral buffered formalin and embedded in paraffin blocks.
Following diagnostic studies and issuance of a standard pathology
Figure 3. An absence of detectable levels of XMRV DNA or
closely related DNA in CWR22 primary prostate tissues was
determined by real-time PCR analysis. Amplification plots from
the real-time PCR analysis of (A) XMRV (FAM) signal in DNA extracted
from different sections of CWR22 prostate tissues and run controls with
the pol and env primer/probe sets; (B) b-globin (Cy5) signal during the
same run.
doi:10.1371/journal.pone.0036072.g003
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Pathology (Case Western Reserve University) at constant room
temperature, mainly in unlighted rooms. In mid-2011, the tissue
blocks were identified though archived hardcopy records as having
originated from patient CWR22 and were then retrieved from
storage. The University Hospitals (Cleveland) Institutional Review
Board allows for the maintenance of patient and sample records
for future studies; with an ability for re-linkage while maintaining a
firewall to prevent release of any public health information to
investigators.
The prostate blocks were sectioned on a microtome used
exclusively for human tissues in the Department of Laboratory
Medicine (Cleveland Clinic). The DNA was extracted in the
Genomic Medicine Institute (Cleveland Clinic) in a laboratory
where neither XMRV nor XMRV nucleic acids were used. To
confirm the common origin of the specimens, the DNA samples
from five FFPE prostate blocks from patient CWR22 (labeled as A,
B, C, E & K) were compared among themselves as well as to the
previously described [35] samples from a CWR xenograft and
22Rv1 cell line by single nucleotide polymorphism (SNP) analysis
at Roswell Park Cancer Institute (Buffalo). We relied on a method
of detecting SNPs using the fully automated system from
Sequenom, Inc. (San Diego, CA). The system is based on PCR-
amplification of the region of interest, followed by primer
extension through the polymorphic site in the presence of three
deoxyribonucleotide triphosphates and one dideoxyribonucleotide
triphosphate, and determination of the nucleotide composition of
the short extension products using mass-spectrometry [40]. We
observed that all the seven samples carried an identical pattern of
SNPs in all thirty of the examined sites (Table 1), thus confirming
that the prostate tissue blocks originated with the same patient as
did the CWR xenograft and 22Rv1 cells.
Absence of XMRV DNA or that of a closely related virus in
patient CWR22
To determine if nucleic acids from XMRV or a closely related
virus was present in the prostate of patient CWR22, PCR was
independently performed in the Department of Cancer Biology,
Cleveland Clinic (Cleveland) and at Abbott Molecular, Inc. (Des
Plaines).
qPCR at Cleveland Clinic. To determine the sensitivities of
qPCR for XMRV gag, pol, and env, assays were done with the full-
length viral molecular clone, plasmid XMRV VP62 [36]. As few
as 15 copies of XMRV plasmid were reproducibly detected with
primers and probes for all three XMRV genes (gag, pol, and
env)(Fig. 1A). Because the nucleotide sequence of XMRV is up to
95% identical with several MLV endogenous proviruse [1], we
sought to determine if qPCR for XMRV gag, pol, and env would
also amplify MLV sequences from mouse DNA. QPCR with
XMRV gag and env primers did amplify products from as little as
100 fg of mouse tail DNA, whereas the XMRV pol primers did not
produce PCR products from mouse DNA (Fig. 1B&C and data
Figure 4. FISH analysis did not detect XMRV nucleic acid or closely related sequences in CWR22 primary prostate tissues. Each slide
was hybridized with a probe mix consisting of XMRV-SO viral probe derived from a full-length XMRV VP62 and CEP8-SA internal control probe from
the centromeric sequence of human chromosome 8. (A) representative image showing XMRV-SO orange staining in a mixture of uninfected DU145
prostate cancer cells and XMRV-infected 22Rv1; (B) the same image showing CEP8-SA aqua staining in DU145 (three copies/cell) and 22Rv1 (two
copies/cell); (C – G) representative images showing XMRV-SO FISH results on tissue sections from blocks A, B, C, E, and K, respectively, from CWR22.
doi:10.1371/journal.pone.0036072.g004
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proviruses can be detected by qPCR with either the XMRV gag
or env primers, but not with the pol primers. To monitor for mouse
DNA contamination, qPCR was performed for mouse IAPs
(endogenous retrovirus-like mobile elements [41] that are readily
detectable by PC [18]). Remarkably, as little as 1 fg of mouse tail
DNA was detected by qPCR for IAP DNA (Fig. 1D). These results
are consistent with the presence of about 50 MLV proviruses [42]
and 1000 copies of IAP DNA per mouse haploid genom [41].
To demonstrate representative fluorescence units as a function
of cycle number, XMRV VP62 plasmid was subjected to qPCR
for XMRV gag, pol, and env in comparison to control reactions
lacking added DNA (Fig. 2A). QPCR assay were performed using
DNA from the different prostate tissue blocks from patient
CWR22. However, no XMRV DNA was detected in duplicate
assays for all three XMRV genes with CWR22 prostate DNA
from blocks A, B, C, E and K (Fig. 2B and Table 2). One of 2
assays for XMRV env in block C only produced a weak response at
.40 cycles, which is below the reliable limit of detection and likely
represents an artifact. No mouse IAP DNA was detected by PCR
of the DNA extracted from the CWR22 prostate tissues indicating
an absence of contaminating mouse DNA in these samples
(Table 2).
Real-time RT-PCR at Abbott Molecular. To further
interrogate the prostate tissue specimens for evidence of XMRV
infection, two additional single-round real-time RT-PCR assays
targeting XMRV pol and env were utilized. Sensitivity and
specificity of the two assays for detection of XMRV have
previously been demonstrated; these were based on comparison
to multiple assays with coded control panels created by the Blood
XMRV Scientific Research Working Group (BSRWG) [37,43].
Using whole blood and plasma panels prepared by the BSRWG,
these assays were equal to the most sensitive assays teste [43].
Using serial dilutions of the XMRV VP62 plasmid controls, both
assays could reliably detect 5 copies of DNA per reaction. Based
on this sensitivity of the assay, we estimate a lower limit of
detection of about 1 proviral genome per 17,000 cells. Positive
control reactions were positive and negative controls were negative
(Fig. 3A). No XMRV was detected by either the pol or env assays in
DNA extracted from CWR22 prostate blocks A, B, C, E and K
(Fig. 3A; Table 2). Signal amplification plots of b-globin (Cy5)
amplified during the same run (Fig. 1B, Table 2) revealed that all
patient samples were positive for b-globin DNA, indicating there
was sufficient DNA present in the samples for amplification.
XMRV FISH analysis of CWR22 tissue sections
An alternative approach for molecular identification of viral
infection is FISH. FFPE tissue sections from each of the CWR22
prostate blocks A, B, C, E and K were screened for evidence of
XMRV infection using a directly-labeled probe (XMRV-SO). The
probe mix also contained a second probe, CEP8-SA, which
hybridizes to the centromeric region of human chromosome 8 that
served as an internal control to monitor the integrity of the FISH
hybridization step. Slides containing a mixture of uninfected
DU145 prostate cancer cells and XMRV-infected 22Rv1 prostate
cancer cells ($10 integrated copies/cell) were used to establish the
specificity and localization of FISH hybridization. Results of this
analysis are shown (Fig. 4A & B). The CEP8-SA chromosomal
marker readily distinguished the two cell lines as three copies were
present in DU145 whereas 22Rv1 contained two copies. XMRV
FISH hybridization was only observed for the 22Rv1 cells.
XMRV-staining in 22Rv1 cells was primarily localized to the
nucleus, while some staining was found in the cytoplasm.
Pretreatment of the cells with RNase A to digest both cellular
and viral RNA prior to hybridization of the XMRV-SO probe
resulted in a punctuate pattern of staining, indicative of integrated
XMRV proviral DNA, localized to the nucleus (data not shown).
Representative images of the XMRV FISH analysis on CWR22
tissue sections from blocks A, B, C, E and K are shown (Fig. 4C–
G, respectively). The tissue sections from blocks B, C and E were
negative for staining with the XMRV-SO probe although they
were positive for the internal control CEP8-SA probe (Fig. 4 and
data not shown). Sections from blocks A and K were negative for
XMRV staining with the exception of some cells along one edge of
each slide. To examine specificity of this staining, a human
papilloma virus probe type 16 probe labeled in the same manner
as the XMRV probe was hybridized to sections from blocks A and
K. Similar to what was observed with the XMRV-SO probe, the
sections were negative with the exception of cells along the same
edge of the slides (data not shown). Thus, the staining observed
along the edge of these slides appears to be a non-specific artifact.
Based on this analysis, we conclude that the sections from all of the
CWR22 tissue blocks are negative for XMRV and related viruses.
Discussion
A previous study proposed that XMRV was generated by
recombination between two endogenous proviruses of mice, pre-
XMRV1 and pre-XMRV2, during passage of the CWR22 tumor
cells in nude mic [30]. While XMRV originated in mice, it is
highly adapted for human prostate epithelial cells as a result of
virus-host cell interactions in vivo. For instance, XMRV trafficked
to prostatic epithelium within 6 or 7 days of experimental infection
of rhesus macaque [44], although not in pigtailed macaques at
119 days post-infectio [45]. Initial infections in the CWR22 cell
lineage that led to the 22Rv1 cell line were likely facilitated by
innate immunity deficiencies. Interestingly, the 22Rv1 cells are
homozygous for the same reduced activity variant of RNase L
(R462Q) as some prostate cancer patients in the original XMRV
stud [1,31]. We confirmed that the primary prostate tissue from
patient CWR22 is QQ for RNase L by genotyping analysis (data
not shown). There is also a deficiency in the host restriction factor
APOBEC3G in 22Rv1 cells and other prostate cancer cell line
[46,47]. In addition, androgen stimulates viral transcription and
replication due to the presence of a glucocorticoid response
element (GRE) in the U3 region of the XMRV LTR [48,49].
Therefore, androgen may have stimulated XMRV infection of
CWR22 cells during passage in male mice. Also, XMRV may
have contributed to the growth of the CWR22 tumors in mic [50].
A limitation of using mouse xenografts to determine the origin
of XMRV is the inevitable presence of low levels of mouse cells
and DNA. We have avoided this complication by studying
primary tissue from the patient as demonstrated by an absence of
mouse IAP sequences. In the current study, five sensitive real-time
PCR assays targeting XMRV gag, pol and env were utilized to
screen for the presence of XMRV in CWR22 prostate cancer
tissue. None of the assays detected XMRV in DNA extracted from
five tissue blocks. Of note, the PCR primers/probe combinations
for XMRV gag and env were capable of amplifying sequences from
mouse DNA but failed to detect evidence of MLV infection in the
prostate of patient CWR22 (with sensitivities as low as 1 viral
genome per 17,000 cells). Similarly, FISH using XMRV DNA as
probe failed to detect viral nucleic acid in the CWR22 tissue. Our
findings conclusively show an absence of XMRV or related viruses
in prostate of patient CWR22, thereby strongly supporting a
mouse origin of XMRV. While XMRV was originally identified in
a study of prostate cancer patients [1], the sequence of XMRV
present in 22Rv1 cells [30] is virtually identical with XMRV
Absence of XMRV in Prostate Tumor CWR22
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contamination with XMRV nucleic acid from 22Rv1 cells as the
source. Further experiments designed to confirm or refute this
hypothesis are currently underway.
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